{"id":31304,"date":"2026-05-04T12:45:33","date_gmt":"2026-05-04T11:45:33","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=31304"},"modified":"2026-05-04T12:45:35","modified_gmt":"2026-05-04T11:45:35","slug":"recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/","title":{"rendered":"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation"},"content":{"rendered":"\n<p>En mars 2026, le Secr\u00e9tariat conjoint quadripartite sur la r\u00e9sistance aux antimicrobiens publie des lignes directrices sur la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation. Ces recommandations fournissent des feuilles de route globales ax\u00e9es sur des objectifs pour d\u00e9velopper et renforcer des syst\u00e8mes de surveillance int\u00e9gr\u00e9e adapt\u00e9s au contexte.<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"590\" height=\"836\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png\" alt=\"\" class=\"wp-image-31305\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png 590w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation-212x300.png 212w\" sizes=\"(max-width: 590px) 100vw, 590px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p>Le rapport revient sur : <\/p>\n\n\n\n<ul>\n<li>la d\u00e9finition et les objectifs de la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation<\/li>\n\n\n\n<li>les cibles microbiennes prioritaires, mesures et indicateurs<\/li>\n\n\n\n<li>les ressources et conditions requises pour impl\u00e9menter une surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb <\/li>\n<\/ul>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-1 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.qjsamr.org\/publications\/9789240109865\" target=\"_blank\" rel=\"noreferrer noopener\">Lire les recommandations<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>En mars 2026, le Secr\u00e9tariat conjoint quadripartite sur la r\u00e9sistance aux antimicrobiens publie des lignes directrices sur la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation. Ces recommandations fournissent des feuilles de route globales ax\u00e9es sur des objectifs pour d\u00e9velopper et renforcer des syst\u00e8mes de surveillance int\u00e9gr\u00e9e adapt\u00e9s [&hellip;]<\/p>\n","protected":false},"author":285,"featured_media":31305,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31,37,26],"tags":[6697,6607,6733,6579,6698,6621],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-04T11:45:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-04T11:45:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png\" \/>\n\t<meta property=\"og:image:width\" content=\"590\" \/>\n\t<meta property=\"og:image:height\" content=\"836\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Aurore Brunet\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Aurore Brunet\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/\"},\"author\":{\"name\":\"Aurore Brunet\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6d6eef4984fc1159096f6dd1f6c2ac41\"},\"headline\":\"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation\",\"datePublished\":\"2026-05-04T11:45:33+00:00\",\"dateModified\":\"2026-05-04T11:45:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/\"},\"wordCount\":138,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png\",\"keywords\":[\"AMR\",\"Antibior\u00e9sistance\",\"Antibiotic Resistance\",\"antimicrobial\",\"Antimicrobial Resistance\",\"OneHealth\"],\"articleSection\":[\"Actualit\u00e9s\",\"Bilans, rapports et recommandations\",\"Infos pratiques &amp; communications\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/\",\"name\":\"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png\",\"datePublished\":\"2026-05-04T11:45:33+00:00\",\"dateModified\":\"2026-05-04T11:45:35+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png\",\"width\":590,\"height\":836},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6d6eef4984fc1159096f6dd1f6c2ac41\",\"name\":\"Aurore Brunet\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/","og_locale":"fr_FR","og_type":"article","og_title":"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2026-05-04T11:45:33+00:00","article_modified_time":"2026-05-04T11:45:35+00:00","og_image":[{"width":590,"height":836,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png","type":"image\/png"}],"author":"Aurore Brunet","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Aurore Brunet","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/"},"author":{"name":"Aurore Brunet","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6d6eef4984fc1159096f6dd1f6c2ac41"},"headline":"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation","datePublished":"2026-05-04T11:45:33+00:00","dateModified":"2026-05-04T11:45:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/"},"wordCount":138,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png","keywords":["AMR","Antibior\u00e9sistance","Antibiotic Resistance","antimicrobial","Antimicrobial Resistance","OneHealth"],"articleSection":["Actualit\u00e9s","Bilans, rapports et recommandations","Infos pratiques &amp; communications"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/","name":"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png","datePublished":"2026-05-04T11:45:33+00:00","dateModified":"2026-05-04T11:45:35+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2026\/05\/Recommandations-quadripartites-relatives-a-la-surveillance-integree-One-Health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation.png","width":590,"height":836},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/recommandations-quadripartites-relatives-a-la-surveillance-integree-one-health-de-la-resistance-aux-antimicrobiens-et-de-leur-utilisation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"Recommandations quadripartites relatives \u00e0 la surveillance int\u00e9gr\u00e9e \u00ab One Health \u00bb de la r\u00e9sistance aux antimicrobiens et de leur utilisation"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6d6eef4984fc1159096f6dd1f6c2ac41","name":"Aurore Brunet"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-05-11 16:26:14","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/31304"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/285"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=31304"}],"version-history":[{"count":1,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/31304\/revisions"}],"predecessor-version":[{"id":31307,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/31304\/revisions\/31307"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/31305"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=31304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=31304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=31304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}